Levodopa was shown to inhibit the proliferation of esophageal squamous cell carcinoma (ESCC) via down-regulating the levels of oxidative phosphorylation proteins which includes MT-CO3, SDHD and NDUFS4 (Li et al., 2020). Here, MT-CO3 is linked to esophageal squamous cell carcinoma.